Sacubitril/Valsartan Improves Progression of Early Diabetic Nephropathy in Rats Through Inhibition of NLRP3 Inflammasome Pathway

References

• Nicola LD, Gabbai FB, Liberti ME, et al. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis. 2014;64(1):16–24. doi:10.1053/j.ajkd.2014.02.010
   Web of Science ®Google Scholar
• Lane PH, Steffes MW, Mauer SM. Renal histologic changes in diabetes mellitus. Semin Nephrol. 1990;10(3):254–259.
   Web of Science ®Google Scholar
• Eugenia E, Irene A, Meritxell I, et al. Renal biopsy in Type 2 diabetic patients. J Clin Med. 2015;4(5):998–1009. doi:10.3390/jcm4050998
   Web of Science ®Google Scholar
• Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in Type 2 diabetes. Jasn. 2013;24(2):302–308.
   Web of Science ®Google Scholar
• Shimizu M, Furuichi K, Yokoyama H, et al. Kidney lesions in diabetic patients with normoalbumi- nuric renal insufficiency. Clin Exp Nephrol. 2014;18(2):305–312.
   Web of Science ®Google Scholar
• Chi HH, Hua KF, Lin YC, et al. IL-36 signaling facilitates activation of the NLRP3 inflammasome and IL-23/IL-17 axis in renal inflammation and fibrosis. J Am Soc Nephrol. 2017;28(7):2022–2037.
   PubMed Web of Science ®Google Scholar
• Krishnan SM, Dowling JK, Ling YH, et al. Inflammasome activity is essential for one kidney/ deoxycorticosterone acetate/salt-induced hypertension in mice. Br J Pharmacol. 2016;173(4):752–765.
   Web of Science ®Google Scholar
• Kadoya H, Satoh M, Sasaki T, et al.Excess aldosterone is a critical danger signal for inflammasome activation in the development of renal fibrosis in mice. FASEB J. 2015;29(9):3899–3910.
   PubMed Web of Science ®Google Scholar
• Packer M, Claggett B, Lefkowitz MP, et al. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018;6(7):547–554.
   PubMed Web of Science ®Google Scholar
• Habibi J, Aroor AR, Das NA, et al. The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat. Cardiovasc Diabetol. 2019;18(1):40. doi:10.1186/s12933-019-0847-8
   PubMed Web of Science ®Google Scholar
• Mohany M, Alanazi AZ, Alqahtani F, et al. LCZ696 mitigates diabetic-induced nephropathy through inhibiting oxidative stress, NF-κB mediated inflammation and glomerulosclerosis in rats. PeerJ. 2020;8:e9196. doi:10.7717/peerj.9196
   PubMed Web of Science ®Google Scholar
• Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477–489. doi:10.1038/s41577-019-0165-0
   PubMed Web of Science ®Google Scholar
• Hutton HL, Ooi JD, Holdsworth SR, et al. NLRP3 inflammasome in kidney disease and autoimmunity. Nephrology. 2016;21(9):736–744. doi:10.1111/nep.12785
   PubMed Web of Science ®Google Scholar
• Muskiet MH, Smits MM, Morsink LM, et al. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol. 2014;10(2):88–103. doi:10.1038/nrneph.2013.272
   PubMed Web of Science ®Google Scholar
• Li Y, Liu J, Liao G, et al. Early intervention with mesenchymal stem cells prevents nephropathy in diabetic rats by ameliorating the inflammatory microenvironment. Int J Mol Med. 2018;41(5):2629–2639. doi:10.3892/ijmm.2018.3501
   PubMed Web of Science ®Google Scholar
• Habib HA, Heeba GH, Khalifa MMA. Effect of combined therapy of mesenchymal stem cells with GLP-1 receptor agonist, exenatide, on early-onset nephropathy induced in diabetic rats. Eur J Pharmacol. 2021;892:173721. doi:10.1016/j.ejphar.2020.173721
   Web of Science ®Google Scholar
• Yaribeygi H, Farrokhi FR, Rezaee R, et al. Oxidative stress induces renal failure: a review of possible molecular pathways. J Cell Biochem. 2018;119(4):2990–2998. doi:10.1002/jcb.26450
   PubMed Web of Science ®Google Scholar
• Rayego-Mateos S, Morgado-Pascual JL, Opazo-Ríos L, et al. Pathogenic pathways and therapeutic approaches targeting inflammation in diabetic nephropathy. Int J Mol Sci. 2020;21(11):3798. doi:10.3390/ijms21113798
   PubMed Web of Science ®Google Scholar
• Pickering RJ, Rosado CJ, Sharma A, et al. Recent novel approaches to limit oxidative stress and inflammation in diabetic complications. Clin Transl Immunol. 2018;7(4):e1016. doi:10.1002/cti2.1016
   PubMed Web of Science ®Google Scholar
• Gnudi L, Coward RJM, Long DA. Diabetic nephropathy: perspective on novel molecular mechanisms. Trends Endocrinol Metab. 2016;27(11):820–830. doi:10.1016/j.tem.2016.07.002
   PubMed Web of Science ®Google Scholar
• Jha JC, Banal C, Chow BS, et al. Diabetes and kidney disease: role of oxidative stress. Antioxid Redox Signal. 2016;25(12):657–684. doi:10.1089/ars.2016.6664
   PubMed Web of Science ®Google Scholar
• Lampropoulou IT, Stangou Μ, Sarafidis P, et al. TNF-α pathway and T-cell immunity are activated early during the development of diabetic nephropathy in Type II diabetes mellitus. Clin Immunol. 2020;215:108423. doi:10.1016/j.clim.2020.108423
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhu X, Li L, et al. A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation. Diabetes Metab Syndr Obes. 2019;12:1297–1309. doi:10.2147/DMSO.S199802
   PubMed Web of Science ®Google Scholar
• Wu M, Han W, Song S, et al. NLRP3 deficiency ameliorates renal inflammation and fibrosis in diabetic mice. Mol Cell Endocrinol. 2018;478:115–125. doi:10.1016/j.mce.2018.08.002
   PubMed Web of Science ®Google Scholar
• Peiró T, Patel DF, Akthar S, et al. Neutrophils drive alveolar macrophage IL-1β release during respiratory viral infection. Thorax. 2018;73(6):546–556.
   Web of Science ®Google Scholar
• Zhang QB, Zhu D, Dai F, et al. MicroRNA-223 suppresses IL-1β and TNF-α production in gouty inflammation by targeting the NLRP3 inflammasome. Front Pharmacol. 2021;12:637415. doi:10.3389/fphar.2021.637415
   Web of Science ®Google Scholar
• Aleissa MS, Alkahtani S, Abd Eldaim MA, et al. Fucoidan ameliorates oxidative stress, inflammation, DNA damage, and hepatorenal injuries in diabetic rats intoxicated with Aflatoxin B1. Oxid Med Cell Longev. 2020;2020:9316751. doi:10.1155/2020/9316751
   Web of Science ®Google Scholar
• Zhang Y. MiR-92d-3p suppresses the progression of diabetic nephropathy renal fibrosis by inhibiting the C3/HMGB1/TGF-β1 pathway. Biosci Rep. 2021;41(9):BSR20203131. doi:10.1042/BSR20203131
   Web of Science ®Google Scholar
• Wada J, Makino H. Innate immunity in diabetes and diabetic nephropathy. Nat Rev Nephrol. 2016;12(1):13–26.
   PubMed Web of Science ®Google Scholar
• Liu H, Chen W, Lu P, et al. Ginsenoside Rg1 attenuates the inflammation and oxidative stress induced by diabetic nephropathy through regulating the PI3K/AKT/FOXO3 pathway. Ann Transl Med. 2021;9(24):1789.
   PubMed Web of Science ®Google Scholar
• Ma L, Wu F, Shao Q, et al. Baicalin alleviates oxidative stress and inflammation in diabetic nephropathy via Nrf2 and MAPK signaling pathway. Drug Des Devel Ther. 2021;15:3207–3221.
   PubMed Web of Science ®Google Scholar
• Sun Z, Ma Y, Chen F, et al. Artesunate ameliorates high glucose-induced rat glomerular mesangial cell injury by suppressing the TLR4/NF-κB/NLRP3 inflammasome pathway. Chem Biol Interact. 2018;293:11–19.
   PubMed Web of Science ®Google Scholar
• Lu H, Bai Y, Wu L, et al. Inhibition of macrophage migration inhibitory factor protects against inflammation and matrix deposition in kidney tissues after injury. Mediators Inflamm. 2016;2016:2174682.
   Web of Science ®Google Scholar
• Bai Y, Wang J, He Z, et al. Mesenchymal stem cells reverse diabetic nephropathy disease via lipoxin A4 by targeting transforming growth factor β (TGF-β)/smad pathway and pro-inflammatory cytokines. Med Sci Monit. 2019;25:3069–3076.
   Web of Science ®Google Scholar
• Wang B, Jha JC, Hagiwara S, et al. Transforming growth factor-β1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. Kidney Int. 2014;85(2):352–361.
   PubMed Web of Science ®Google Scholar
• Zheng W, Qian C, Xu F, et al. Fuxin Granules ameliorate diabetic nephropathy in db/db mice through TGF-β1/Smad and VEGF/VEGFR2 signaling pathways. Biomed Pharmacother. 2021;141:111806.
   Web of Science ®Google Scholar
• Xu J, Xiang P, Liu L, et al. Metformin inhibits extracellular matrix accumulation, inflammation and proliferation of mesangial cells in diabetic nephropathy by regulating H19/miR-143-3p/TGF-β1 axis. J Pharm Pharmacol. 2020;72(8):1101–1109.
   PubMed Web of Science ®Google Scholar
• Sun Z, Ma Y, Chen F, et al. miR-133b and miR-199b knockdown attenuate TGF-β1-induced epithelial to mesenchymal transition and renal fibrosis by targeting SIRT1 in diabetic nephropathy. Eur J Pharmacol. 2018;837:96–104.
   PubMed Web of Science ®Google Scholar
• Pourghasem M, Shafi H, Babazadeh Z. Histological changes of kidney in diabetic nephropathy. Caspian J Intern Med. 2015;6(3):120–127.
   PubMed Web of Science ®Google Scholar
• Sean Eardley K, Cockwell P. Macrophages and progressive tubulointerstitial disease. Kidney Int. 2005;68(2):437–455.
   Web of Science ®Google Scholar
• Poczatek MH, Hugo C, Darley-Usmar V, et al. Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1. Am J Pathol. 2000;157(4):1353–1363.
   PubMed Web of Science ®Google Scholar
• Miao XJ, Bi TT, Tang JM, et al. Regulatory mechanism of TGF-β1/SGK1 pathway in tubulointerstitial fibrosis of diabetic nephropathy. Eur Rev Med Pharmacol Sci. 2019;23(23):10482–10488.
   Web of Science ®Google Scholar